CONTENTS
Chapter 5 Clinical management 14-24 5.1 Grading the severity of Dengue infection 14 5.2 Management 15 5.2.1 Management of Dengue fever (DF) 15-16
Download CONTENTS
Information
Domain:
Source:
Link to this page:
Documents from same domain
SOP – Malaria Microscopy - NVBDCP
nvbdcp.gov.inQuality Assurance of Malaria Diagnostic tests SOP – Malaria Microscopy © Copyright to Dte. NVBDCP Only. Any modification are prohibited ACKNOWLEDGEMENTS Each and every laboratory working under the NVBDCP must produce accurate, reliable
GUIDELINES FOR INTEGRATED VECTOR …
nvbdcp.gov.inGUIDELINES FOR INTEGRATED VECTOR MANAGEMENT FOR CONTROL OF DENGUE / DENGUE HAEMORRHAGIC FEVER Govt of India National Vector Borne Disease Control Programme,
Diagnosis and Treatment of Malaria in India
nvbdcp.gov.inGuidelines for Diagnosis and Treatment of Malaria in India 2009 Government of India National Vector Borne Disease Control Programme National Institute of Malaria
National Programme for Prevention and Control of …
nvbdcp.gov.inOperational Guidelines National Programme for Prevention and Control of Japanese Encephalitis/ Acute Encephalitis Syndrome Government of India
ASHA - PAYMENT REGISTER AT PHC FOR MALARIA
nvbdcp.gov.inSl No Subcentre Name of ASHA ASHA Code No. of Slides Collected (a) Incentive @ 5/- per slide (b =aX5) No. Of RDT Pos Cases Treated (c) Incentive @ 20/-
Diagnosis and Treatment of Malaria in India
nvbdcp.gov.inlong acting antimalarial (amodiaquine, lumefantrine, mefloquine or sulfadoxine-pyrimethamine). The ACT used in the national programme in India is artesunate + sulfadoxine-pyrimethamine (SP). Presently, Artemether + Lumefantrine fixed dose combination and blister pack of artesunate + mefloquine are also available in the country.
Diagnosis and Treatment of Malaria - NVBDCP
nvbdcp.gov.inmalaria To prevent deaths from severe and complicated malaria To prevent transmission of malaria To minimize risk of spread of drug resistant parasites by use of effective drugs in appropriate dosage by everyone. Diagnosis and Treatment for Malaria Diagnosis &Treatment All fever cases diagnosed as malaria by either RDT or microscopy should be ...
NATIONAL VECTOR BORNE DISEASE CONTROL …
nvbdcp.gov.inThe National Vector Borne Disease Control Programme (NVBDCP) is an umbrella programme for prevention and control of vector borne diseases viz. Malaria, Japanese Encephalitis (JE), Dengue, Chikungunya, Kala-azar and Lymphatic Filariasis. Out …
Related documents
National Institutes of HealtDEPARTMENT OF HEALTH AND …
consensus.nih.govU.S. NIH Consensus Development Conference on Celiac Disease June 28 − 30, 2004 William H. Natcher Conference Center National Institutes of Health
TIP 40: Clinical Guidelines for the Use of Buprenorphine ...
lib.adai.washington.eduTIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40
Supported by: national autism standards ard The ...
www.aettraininghubs.org.uknational autism standards a rds www.autismeducationtrust.org.uk Supported by: 2 training of clinical and educational psychologists and specialised in children who had communication and
National Standard Curriculum - cccfiretraining.com
www.cccfiretraining.comContract Number DTNH22-95-C-05108 EMT-PARAMEDIC: NATIONAL STANDARD CURRICULUM Project Director Walt A. Stoy, Ph. D., EMT-P Associate Professor and Chair
Constructing Written Test Questions For the Basic and ...
www.nbme.orgConstructing Written Test Questions For the Basic and Clinical Sciences National Board of Medical Examiners 3750 Market Street Philadelphia, PA 19104
Results of the 2016 NRMP Program Director Survey
www.nrmp.orgIntroduction NRMP Program Director Survey Results, 2016 1 In March 2016, the National Resident Matching Program (NRMP) conducted its biennial survey of the directors of all
DON’T NEED A CLINICAL TRIAL FOR A CE MARK? THINK AGAIN
www.nsaiinc.comDON’T NEED A CLINICAL TRIAL FOR A CE MARK? THINK AGAIN Nashua, New Hampshire, March 30, 2009 – If you want to sell your medical device in Europe, you need to have a CE Mark.
National Anti-retroviral Therapy Guidelines - WHO
www.who.intNational ART Guidelines 2009 Page 4 Dr. Laxmi Raj Pathak, Director, NCASC Dr. Krishna Kumar Rai, Director, NCASC Dr. Ramesh Kharel, Deputy Director, NCASC